A report out in Politico that discusses the use of distributed autonomous organizations in clinical trials. Politico points out that modern healthcare has a problem: many diseases…
Agnostic to location and time for clinical decision-making, enshrined within federate data networks, and with equitable access by patients, care providers and researchers, aided by machine learning and transparent AI to interpret and ensure security
AI and IoMT embedded in smart contracts for clinical setting, blockchain based dynamic consent and other decentralised features of future clinical trials. All this is native to young researchers now, read an example of their vision
Consolidation instead of centralization, Denmark as a data dream, interoperability as happiness. Read Part 1 of the interview with Jens Winther Jensen, the Danish Clinical Quality Programme CEO
Pills with cameras and clinical grade wearables to communicate with your lifestyle smartwatches. IoMT classification and advantages, the second text in the series on the Internet of Medical Things
What new uses of biomarkers to expect in the future? We look into the past, present and possible futures of analogue and digital biomarkers in clinical settings and outside them
